Krystal Biotech (KRYS) Income from Continuing Operations (2016 - 2026)
Krystal Biotech (KRYS) reported Income from Continuing Operations of 55942000.0 for Q1 2026, up 56.56% on a YoY basis from 35733000.0 in Q1 2025, and up 8.86% sequentially from 51391000.0 in Q4 2025.
Krystal Biotech (KRYS) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Krystal Biotech (KRYS) has 11 years of Income from Continuing Operations data on file, last reported at 55942000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 56.56% year-over-year to 55942000.0; the trailing twelve-month figure through Mar 2026 stood at 225073000.0 (up 81.59% YoY), and the FY2025 full-year result was 204831000.0, up 129.74% from the prior year.
- Income from Continuing Operations grew to 55942000.0 in Q1 2026, from 51391000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 80747000.0 in Q3 2023 to a low of 114315000.0 in Q1 2023.
- A 5-year average of 2952235.29 and a median of 15568000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 173.27% in 2022 and soared 3734.01% in 2025, its largest moves.
- Tracing KRYS's Income from Continuing Operations over 5 years: stood at 34024000.0 in 2022, then soared by 125.55% to 8692000.0 in 2023, then jumped by 423.23% to 45479000.0 in 2024, then grew by 13.0% to 51391000.0 in 2025, then rose by 8.86% to 55942000.0 in 2026.
- Business Quant data shows KRYS's Income from Continuing Operations at 55942000.0 in Q1 2026, 51391000.0 in Q4 2025, and 79365000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Krystal Biotech | 9.84 Bn | 9.02 Bn | 110.08 Mn | 55.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.94 Mn |
| Dec 31, 2025 | 51.39 Mn |
| Sep 30, 2025 | 79.37 Mn |
| Jun 30, 2025 | 38.38 Mn |
| Mar 31, 2025 | 35.73 Mn |
| Dec 31, 2024 | 45.48 Mn |
| Sep 30, 2024 | 27.17 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | 932,000.00 |
| Dec 31, 2023 | 8.69 Mn |
| Sep 30, 2023 | 80.75 Mn |
| Jun 30, 2023 | -33.21 Mn |
| Mar 31, 2023 | -114.32 Mn |
| Dec 31, 2022 | -34.02 Mn |
| Sep 30, 2022 | -68.59 Mn |
| Jun 30, 2022 | -57.44 Mn |
| Mar 31, 2022 | -81.62 Mn |
| Dec 31, 2021 | -22.03 Mn |
| Sep 30, 2021 | -25.10 Mn |
| Jun 30, 2021 | -39.26 Mn |